Fewer Drugs Have Unsupported Price Increases, ICER Finds
-
Dec 24, 2024
In its sixth annual Unsupported Price Increases (UPI) report, the Institute for Clinical and Economic Review (ICER) found that five of the top 10 drugs with substantial net price increases in 2023 did not have adequate clinical evidence to support the increases. That was the fewest number of drugs with unsupported price increases in the six years of the report and was down from eight out of 10 in last year’s report.
The other five drugs with substantial net prices did have new clinical evidence last year, which manufacturers could use to justify the net price increases. However, ICER noted it did not conduct a thorough analysis to determine whether the price increases met its strict cost-effectiveness criteria.
Read more
© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.